Anti-fibrinolytic therapy of giant hypertrophic gastritis (Menetrier's disease).
In five cases of giant hypertrophic gastritis (Menetrier's disease) biopsied gastric mucosa was examined for fibrinolytic activity; in all cases there was marked elevation of the activity due mainly to tissue plasminogen activator. The patients were given antifibrinolytic therapy with oral tranexamic acid (trans-4-aminomethyl cyclohexane carboxylic acid; trans-AMCHA), and four of the patients showed marked improvement of their hypoproteinemia as well as their mucosal disorders. One patient, who showed moderate increase of serum protein level but no reduction of the mucosal disorder, finally received gastrectomy. It was concluded that antifibrinolytic therapy seemed to block the vicious circle of 'membrane disorders', 'increased tissue fibrinolysis', 'increased vascular permeability' and 'hypoproteinemia' in Menetrier's disease.
D000328:Adult; D002986:Clinical Trials as Topic; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects; D005753:Gastric Mucosa / Q000378:metabolism; D005756:Gastritis / Q000188:drug therapy*; D006801:Humans; D006984:Hypertrophy; D008297:Male; D008875:Middle Aged; D010960:Plasminogen Activators / Q000378:metabolism; D011504:Protein-Losing Enteropathies / Q000188:drug therapy; D014148:Tranexamic Acid / Q000627:therapeutic use*
D003509:Cyclohexanecarboxylic Acids; D014148:Tranexamic Acid; D010960:Plasminogen Activators